hold on there's just too much going on in Congress lmao...
Creates government institute to develop and sell affordable drugs/devices.
Rep. Tlaib (D-MI), Rep. Lee (D-PA), and Rep. Cherfilus-McCormick (D-FL).
Introduced in House, awaiting committee review.
This bill proposes establishing a National Institute for Biomedical Research and Development. This new government body would develop drugs, devices, and biological products with the goal of making them available at equitable and accessible prices. The bill was introduced by Representative Rashida Tlaib, a Democrat from Michigan, along with two other Democratic co-sponsors. It has been referred to two House committees, Energy and Commerce and Judiciary, for further consideration.
Introduced Mar 5, 2026
The bill was introduced in the House of Representatives on March 5, 2026. It has since been referred to the House Committee on Energy and Commerce and the House Committee on the Judiciary. Before it can be voted on by the full House, it must be reviewed and approved by these committees. If it passes the House, it would then move to the Senate for their consideration.
If this bill becomes law, a new government institute would be created to research, develop, and even manufacture essential drugs and medical devices. This could lead to a decrease in the cost of certain medications and devices, as the institute would aim to sell products at cost or license patents with cost-plus pricing. Additionally, you would see greater transparency in how medicines are developed, with more research data, clinical trial results, and licensing agreements being made publicly available.
Supporters Say
Supporters believe it would lower drug costs and prioritize public health needs by establishing a government research and manufacturing institute.
Critics Say
Critics might argue against government involvement in drug development, citing concerns about market interference or efficiency.
Those in favor of the bill argue it will address the high cost of prescription drugs and medical devices by creating a public option for development and manufacturing, focusing on unmet health needs over profit. They point to the bill's goals of 'equitable and accessible prices' and 'prioritization of public health needs.' On the other hand, opponents might raise concerns about the government's ability to efficiently manage complex biomedical research and development, potentially stifling innovation from private companies or leading to unintended consequences in the pharmaceutical market.